Further to the intimation dated January 23, 2023, on the audit conducted by the United States Food and Drug Administration (USFDA) at its Solid Oral Formulation Facility (Plant 1) at Goa, from January 16, 2023 to January 20, 2023, Indoco Remedies has informed that the Company has received the Establishment Inspection Report (EIR) indicating closure of the inspection. It has enclosed press release in this regard.
The above information is a part of company’s filings submitted to BSE.